initi coverag outperform rate believ
magenta pipelin candid potenti improv sever aspect stem
cell transplant could transform access transplant expect
share appreci multipl candid advanc develop
allogen stem cell transplant invent year ago process
remain larg unalt today gener devoid formal fda approv magenta
seek improv sever aspect transplant process includ donor
identif stem cell donat toxic condit regimen risk
graft vs host diseas capabl develop stand-alone product
combin pipelin power fundament alter abil patient
stem cell obtain sever sourc includ bone marrow aspir
peripher blood cord blood hundr thousand cord frozen cord blood
bank unfortun contain stem cell usabl adult transplant
patient expans protocol result increas stem cell therefor
could make much bank cord usabl adult patient
significantli increas likelihood patient find suitabl match cord blood bank
current phase ii develop think could support
peripher blood base stem cell donat current reli upon administr g-
csf /- plerixafor mobil stem cell unpredict process take
day week unpredict lead much donor/pati inconveni
lost revenu apheresi center seek turn peripher donat
predict singl day process enter clinic could rapidli
gener proof-of-concept data think could support sale
magenta three antibodi drug conjug develop use condit
patient receiv stem cell transplant process current use high dose
chemotherapi /- irradi gener much toxic leav patient
perman organ damag magenta plan deploy adc select elimin host
stem cell make room incom transplant spare heart lung
reproduct organ think program sale potenti
pleas see page report import disclosur
mani patient could benefit stem cell transplant unabl
access one magenta multifacet pipelin seek systemat alter paradigm
improv patient abil find donor toler procedur think
program aggreg sale potenti initi data indic
dramat increas util cord blood enter clinic
could rapidli gener proof-of-concept chemotherapi spare condit regimen
enter clinic expect stock outperform mileston
program achiev
initi phase ii data imd
data mobil stem cell
present non-human primat data
major player cord blood
cord blood remain minor
increas cord blood share overal
magenta product fail gener
cord blood lose market share
becom first line option
condit regimen wide
adopt exist transplant market
share first line stem cell
expans transplant market
payor unwil pay
magenta lead transplant medicin compani combin
academ harvard industri heidelberg pharma novarti sourc magenta
assembl broad pipelin transplant medicin seek alter abil locat
suitabl stem cell donat stem cell collect toxic transplant
procedur bring product market magenta aim transform transplant
medicin greatli reduc toxic expand access transplant
hematopoiet stem cell transplant cur treatment mani condit
disord autoimmun diseas inborn error metabol howev transplant
use transplant potenti gener cure thought
superior possibl altern non-transpl therapeut
differenti justifi signific acut chronic burden includ
death associ receiv transplant result mani patient unabl
magenta lead transplant medicin compani
combin academ harvard industri heidelberg pharma novarti
sourc magenta assembl broad pipelin transplant medicin seek
alter abil locat suitabl stem cell donat stem cell collect
toxic transplant procedur bring product market magenta
aim transform transplant medicin greatli reduc toxic expand
access transplant
magenta pipelin consist one clinic candid preclin program
magenta plan total three clinic program compani
advanc candid acquir novarti expand cord blood
stem cell product phase ii test think potenti
greatli expand util bank umbil cord could support sale
magenta also late preclin program stem cell mobil
seek streamlin increas reliabl stem cell donat think
program could support sale perhap excit magenta trio
antibodi drug conjug target target
undisclos target adc develop use chemo/radi
spare condit agent seek decreas acut chronic toxic
condit regimen util high dose chemotherapi radiat
increas efficaci transplant applic direct anti-tumor kill
think program could support annual sale within myeloid
malign aml/md alon annual sale wider transplant market
magenta also on-going research program prevent graft vs host
diseas gvhd success develop product use independ
manag also envis transplant patient access mani four differ
magenta product journey transplant clinic abil offer
transplant physician sever product creat highli leverag sale forc
perhap importantli potenti dramat alter risk benefit
transplant occur transplant could becom standard therapi rang new
indic like multipl sclerosi expand overal transplant market
increas sale potenti product
cowen compani
magenta complet ipo june inclus net proce
compani financ sever mileston across pipelin
achiev poc non-human primat base condit
initi investig sponsor phase ii trial leukemia/lymphoma
non-human primat transplant data mobil stem cell
present initi clinic data phase ii trial patient metabol disord
present non-human primat data
select final clinic candid program
potenti sign gene therapi and/or edit partnership base stem cell expans
initi phase ii trial sickl cell diseas
initi phase ii data sickl cell diseas
achiev poc non-human primat base condit
complet ind enabl studi
achiev poc non-human primat contain condit regimen
initi healthi volunt studi
initi data healthi volunt studi
file ind
initi phase trial aml/md
initi phase i/ii trial mobil stem cell multipl myeloma nhl
initi data phase i/ii trial mobil stem cell multipl myeloma nhl
initi phase studi metabol disord
cowen compani
compani sport market cap estim pro-forma
enterpris valu compani plan initi pivot trial
model reach market possess peak sale
potenti rapid develop path possibl
assum clinic outcom requir result commerci launch
peak sale base upon npv analysi estim product
opportun plu cash worth repres upsid
mgta recent close price
think magenta chemotherapi spare condit regimen also
potenti fundament alter risk benefit analysi stem cell transplant
could provid addit upsid unfortun asset remain lead
optim clinic develop path defin new paradigm
dispar diseas less well defin therefor find difficult attach
commerci date program quantifi exact sale opportun
consult believ lowest hang fruit program improv
outcom myeloid malign aml md think opportun
alon repres peak sale opportun therefor anticip
share outperform magenta program advanc clinic particular
valu condit regimen becom clearer
cowen compani
financi year growth ex-u total free year growth valu termin valu net dilut share per fulli dilut valu calcul cowen
cowen compani
cowen compani
regimen grant rate incom incom regimen grant rate incom incom cowen
magenta clinical-stag biotechnolog compani develop medicin
expand util hematopoiet stem cell transplant improv
access safeti toxic transplant stem cell transplant use treat
sever autoimmun disord blood cancer genet diseas cur
howev use transplant limit challeng includ obtain suffici
cell morbid mortal prepar patient transplant
molecul cell therapi meant address limit
improv magenta aim improv outcom transplant use today
expand elig patient popul within indic increas number
condit treat bone marrow transplant improv stem cell dose
access cord blood deriv stem cell magenta develop
expand cord blood product achiev proof concept patient
blood cancer phase ii trial patient inherit metabol diseas
therapi aim improv mobil stem cell use
transplant perhap revolutionari compani condit program
design select remov stem cell and/or immun cell patient
transplant less toxic radiat chemotherapy-bas treatment
constitut current standard care final post-transpl complic
program target donor immun cell within patient caus graft vs host diseas
gvhd fatal expect share outperform magenta program
advanc develop magenta systemat improv transplant process
bone marrow tissu insid bone hematopoiet stem cell hsc found
pluripot cell produc cell blood immun system cell
resid bone marrow constantli produc new red white blood cell
replac die cell peripheri stem cell transplant use either replac
diseas stem cell and/or diseas progeni healthi stem cell healthi
blood compart success transplant potenti cur therapi
blood cancer like leukemia lymphoma inherit diseas hurler
syndrom sickl cell diseas well autoimmun disord includ multipl
sclerosi scleroderma transplant involv multistep process includ
intens care/monitor immun system reconstitut physician
select menu option mani step base upon underli
diseas treat patient risk factor etc one million patient undergon
procedur sinc incept approxim patient
transplant classifi either autolog patient allogen
relat unrel stem cell donor base upon ident stem cell sourc
autolog allogen stem cell obtain bone marrow aspir
peripher blood umbil cord blood allogen stem cell transplant also
divid base upon degre hla gene donor cell match
stem cell obtain patient condit accept new stem
cell condit involv reduc elimin patient preexist stem cell
order make space donor cell engraft expand reconstitut new
blood compart two major type condit regimen myeloabl
larg dose chemotherapi and/or radiat reduced-intens
partial erad malignancy/stem cell allow immunolog recognit
remain cancer/stem cell donor immun system
stem cell deliv new blood cell grow period two four week
time immun system also rebuilt process take much
longer patient immunocompromis state suscept common
germ fungi sever week month period increas suscept
infect requir extens intervent limit likelihood infect rapidli
react infect occur effort includ keep patient isol
intens monitor and/or use prophylact antibiotics/antivir immun
reconstitut also possibl new immun system recogn begin
attack recipi call graft vs host diseas gvhd occur
either acut day post-transpl chronic day set gvhd
major contributor morbid mortal associ stem cell
though stem cell transplant capabl provid cur benefit procedur
come signific risk includ infect gvhd secondari cancer death
result transplant arent perform elig patient concern
risk outweigh benefit magenta note two everi three elig
patient acut myeloid leukemia dont receiv transplant despit procedur
consid standard care even fewer patient sickl cell diseas
offer procedur therefor manag hope systemat improv
stem cell transplant process shift risk benefit equat transplant
greatli expand use
monocyt lymphocyt natur killer cell etc form bone
marrow progenitor hematopoiet stem cell hsc process known
hematopoiesi hsc gener found rest state close associ
stromal cell upon receipt growth signal hsc capabl divid self-renew
differenti blood cell need abil self-renew form
complet blood compart leverag develop hsc therapeut use
includ transplant recent ex vivo gene therapi involv
introduct gene small number hsc reintroduc
patient propag desir gene throughout blood/immun system
find match donor allogen transplant collect enough stem cell
two challeng bone marrow transplant latter point obtain suffici
number cell import due correl higher cell dose better
engraft rate long-term outcom optim donor recipi
compat base upon respect repertoir human leukocyt antigen
hla hla system made cell-surfac protein respons immun
system regul hla correspond one three class major
histocompat complex molecul correspond mhc class
gener present peptid insid cell digest protein broken
proteasom killer t-cell hla correspond mhc class ii dp dm
dq dr gener present antigen outsid cell helper t-
cell hla correspond mhc class encod compon complement
system gener ignor transplant importantli hla gene
among divers human genom gene hundr
allel found throughout globe
mhc molecul critic compon immun system process
differenti healthi infect cell mismatch result catastroph
autoimmun gvhd inabl recogn fight key pathogen fact
increas mismatch associ higher rate gvhd higher rate graft
failur histor data indic mismatch class ii thought
reduc overal surviv five year approxim consequ center type
patient ten hla allel five gene loci hla-a -b -c
attempt identifi donor match mani possibl note
hla match evolv field knowledg rel clinic import
allel improv fact recent data question util suggest
dp haplotyp may greater import previous
match donor identifi rel recipi sibl
chanc full match found nation registri search though
perfect hla match often possibl near-tot match allel import
given level discrep hla correl risk gvhd
approxim half patient elig transplant abl find match donor
registri howev divers hla allel vari significantli across ethnic
group caucasian overrepres registri result likelihood
identifi donor vari ethnic caucasian patient
western european descent find match patient african descent
given gvhd primarili cell mediat research previous hypothes
incid may reduc elimin lymphocyt donor
inoculum cell deplet transplant howev earli attempt associ
increas graft failur delay immun reconstitut associ increas
infecti complic diseas relaps lymphoprolif disord result
reduct gvhd balanc increas complic extent
signific benefit long-term outcom recent attempt
yield better result select add back cell donor lymphocyt
infus complic cmv infect aris studi shown
higher number regulatori cell and/or natur killer cell graft associ
improv outcom term immun reconstitut reduc gvhd
infect therefor modul cell content donat remain activ
area research
order use hsc therapeut purpos must first obtain
patient donor histor done direct harvest hsc
bone marrow bone marrow harvest typic perform via aspir
posterior iliac crest anesthesia bone marrow also found anterior
iliac crest though amount limit often multipl aspir perform
order collect marrow per kilogram recipi bodi weight
bone marrow adult howev nation marrow donor
program limit volum bone marrow remov donor weight
complic bone marrow harvest includ mild back hip pain fatigu
transient chang peripher blood cell count rare donor experi injuri
complic anesthesia infect bleed aspir
obtain hsc isol milieu stromal cell use
cell surfac marker though exact surfac phenotyp hsc topic on-going
debat clinic trial demonstr popul cell
capabl support long term hematopoiesi follow autolog hematopoiet cell
transplant therefor surfac marker use track harvest
purif hsc
hsc also mobil bone marrow peripher blood use
granulocyt colony-stimul factor g-csf filgrastim though hsc typic
detect peripher blood low level growth factor requir
produc adequ quantiti transplant administr growth factor
hsc coax exit bone marrow expand frequenc
within peripher blood increas process typic allow
suffici quantiti hsc obtain apheresi procedur donor
fail mobil adequ number cell g-csf alon plerixafor
mozobil ad addit plerixafor gener result suffici
dose obtain within addit day stimul fda approv
plerixafor use brand name mozobil stem cell mobil
remain mozobil approv use product gener global sale
despit sanofi deploy sale forc support use
peripher donor experi risk associ apheresi g-csf
administr splenomegali although complic fairli uncommon
consult report typic peripher stem cell mobil procedur cost
although note subject requir mozobil significantli expens
addit opportun cost apheresi chair reserv multipl
day ultim use due insuffici count
approxim million donor regist world-wide
express willing undergo bone marrow peripher blood harvest
preliminari hla-a serolog type conduct howev registri
account possibl hla combin class allel
class ii allel yield sever million potenti combin difficulti
find hla match underrepresent certain ethnic group
blood bank african asian popul hla polymorph
greater divers haplotyp complet search match unrel donor
take sever month howev predict algorithm use give
estim likelihood find match preliminari search perform
quickli
hsc obtain umbil cord blood ucb well importantli ucb
process cryopreserv cord blood bank well advanc use
transplant cord blood bank privat public public bank collect blood
limit number hospit california connecticut state collect
program public cord blood bank store donat cord recoup cost sell
process stem cell hospit administ transplant cord public bank
cost privat for-profit bank collect store cord blood
famili want access stem cell child anoth famili member need
bank reli obstetrician midwif collect blood
sent central process lab blood reserv famili use
famili charg collect storag though durat viabil store
cord blood unknown report children receiv cord blood
store three year show correl storag time
time engraft therefor set shelf life cord blood age
public cord blood bank benefit contain larg donor pool readi
near immedi use compar peripheral/bon marrow harvest requir
confirm donor consent potenti delay extend mobil
procedur umbil cord blood also known decreas rate graft vs host
diseas gvhd therefor complet hla match isnt need howev umbil
cord blood come increas risk graft failur delay immun reconstitut
unavail donor repeat donat donor lymphocyt infus
rescu graft failur importantli transplant outcom meaning impact
number hsc cord blood number hsc correl cord
blood volum collect volum vari base matern fetal characterist
addit technic aspect collect process heavier babi women
fewer previou live birth higher cell count exampl
umbil cord blood unit enough stem cell use adult result adult
receiv cord blood transplant gener receiv doubl cord transplant
util cord two independ donor also decreas odd graft failur
one two new immun system requir success transplant
unfortun use second cord also increas risk graft-versus-host diseas
anoth option haploident donat parent children sibl first degre
rel modifi form stem cell transplant haploident transplant requir
hla match widen pool possibl donor found haploident
donor often readili avail make donat speed time
transplant hla match would typic result rapid profound gvhd
cell present donat haploident transplant procedur reli upon
gap time expans gvhd mediat cell present graft
outgrowth fulli educ nave cell donat hsc
interven period haploident transplant recipi administ high dose
cytoxan chemotherapi kill activ cell elimin much gvhd
risk match success rate appear similar convent transplant though
persist effect still studi rel eas identifi
haploident donor patient led procedur rapidli adopt
follow develop consult report
combin match donor haploident donor cord blood suitabl
sourc ultim identifi nearli patient transplant
autolog transplant center use peripher blood base two studi
patient relaps lymphoma randomli assign receiv peripher
progenitor cell bone marrow peripher blood found yield superior
engraft outcom limit blood volum children complic
harvest autolog hsc therefor popul avail
match cord blood sampl privat bank particularli use
allogen transplant outcom depend patient underli condit stage
diseas comorbid like cmv seroposit time transplant donor
depend urgenc transplant patient may compromis hla match
interest postpon treatment gener donor select proce use
patient full sibl hla match
unrel donor match
cord blood unit hla mismatch donor relat
algorithm base retrospect analys demonstr efficaci
treatment approach howev studi limit valid given
differ patient condit treatment group non-random
natur trial on-going random control phase trial bone marrow vs
umbil cord blood transplant patient hematolog malign
conduct blood marrow transplant clinic trial network studi
compar progression-fre surviv two year post-random patient
receiv unrel doubl cord blood unit transplant vs hla-haploident
relat bone marrow transplant data trial expect around year-end
consult expect trial demonstr non-inferior haploident
transplant given cost differenti haploident cord transplant
consult view outcom de facto find superior haploident
transplant importantli consult indic market alreadi reflect
presum outcom center search haploident donor prior
pursu cord blood fact center also begin priorit haploident
donor ahead match unrel donor
non-cord blood base transplant bone marrow peripher blood base
harvest gener select base upon donor/pati prefer patient
high risk graft failur infect peripher blood may prefer
order gener rapid hematopoiet recoveri bone marrow may use
case advanc diseas high risk relaps due evid
random trial demonstr peripher blood associ faster
engraft neutrophil platelet higher rate gvhd howev
cochran meta-analysi nine random trial report choic stem cell
sourc impact overal surviv disease-fre surviv transplant-rel
suffici number donor stem cell acquir recipi
condit transplant use system chemotherapi without radiat
prepar regimen prior transplant aim significantli reduc
elimin residu diseas prior introduct new healthi cell
provid space bone marrow within donor hsc engraft may
perform use myeloabl regimen reduc intens condit ric
nonmyeloabl nma regimen myeloabl regimen caus self-limit side
effect nausea vomit mucos alopecia addit perman damag
tissu like lung liver organ secondari cancer long-term
effect concern repres drive forc behind attempt develop
rational regimen lower toxic profil follow discoveri
case cancer cell erad entir high dose chemotherapi
alon mani long-term tumor respons prompt donor
allograft gener immun respons residu tumor known
graft-versus-tumor effect gvt research indic gvt effect significantli
reduc risk relaps follow allogen transplant otherwis rel
high patient undergo autolog transplant vs
undergo allogen transplant howev clinic evid suggest diseas
suscept gvt other follicular lymphoma chronic lymphocyt
leukemia mantl cell lymphoma chronic myeloid leukemia respons
acut lymphoblast leukemia hodgkin lymphoma resist
research requir differenti effect transplant approach
patient age comorbid aggress underli diseas
nma regimen includ flu/tbi fludarabin low dose total bodi
irradi tli/atg total lymphoid irradi anti-thymocyt globulin
mg/kg ric regimen slightli myeloabl includ flu/mel
fludarabin melphalan fludarabin busulfan flu/ci fludarabin
cyclophosphamid flu/bu/tt fludarabin busulfan thiotepa
phase trial aml myelodysplast syndrom patient found myeloabl
regimen associ superior relapse-fre surviv rf rel ric
vs statist differ overal surviv month due
higher rate treatment-rel mortal vs illustr delic
balanc achiev maxim efficaci direct anti-tumor effect
condit regimen limit toxic toler level therefor
consult report select condit regimen base upon
combin factor includ underli diseas patient statu physician
step stem cell infus engraft
condit complet stem cell infus patient infus bone
marrow peripher blood perform central vein sever hour
autolog product cryopreserv product gener thaw clinic
infus quickli sever minut process stem cell
engraft bone marrow caviti infus poorli understood
thought involv vascular cell adhes heparin sulfat
fever typic procedur well toler
engraft opportunist infect gvhd engraft take two
six week depend dose stem cell infus time patient
increas risk infect bacteri fungal viral must remain
hospit special isol room high cost hospit system
immun system adequ reconstitut measur white blood cell
count patient said achiev engraft remov isol
potenti discharg hospit graft failure/reject common
stem cell dose low occur commonli cord blood
transplant situat patient high risk death second
transplant perform result engraft case cord blood
transplant donor recal second donat therefor back-up cord
must obtain advanc process identifi donor obtain
cell must start scratch second donor rapidli identifi patient
graft-versu host diseas gvhd common complic transplant occur
immun cell transplant donor recogn recipi tissu
foreign prompt immun reaction acut gvhd classic present within
day transplant rash nausea abdomin cramp diarrhea rise serum
bilirubin gvhd occur day typic classifi chronic
later present differ set symptom skin chang similar lichen planu
dri oral mucosa ulcer sclerosi gastrointestin tract rise
serum bilirubin howev distinct acut chronic increasingli
made base upon symptom time diseas onset
rate gvhd vari base degre hla dispar donor
recipi gender dispar intens condit regimen acut gvhd
prophylact regimen sourc graft
autoimmun disord typic caus patient adapt immun system
cell begin recogn attack normal healthi tissu immun insult
lead gener aberr immun respons unknown howev
propos reset immun system respons
elimin potenti recur data publish lancet report
multipl sclerosi ms patient receiv autolog transplant
ottawa hospit research institut patient year preced transplant
patient experienc total clinic relaps median follow-up
year relaps observ new gadolinium enhanc lesion
detect patient achiev primari endpoint ms activ free
surviv one patient die transplant relat complic european group
blood marrow transplant ebmt autoimmun diseas work parti
also conduct random phase ii astim trial autotranspl vs mitoxantron
secondari progress relapsing-remit ms patient trial demonstr
reduct number new lesion year post-
addit case report small case seri publish number
autoimmun disord decad sinc invent stem cell transplant
review data focu ms system sclerosi scleroderma
publish total ms studi shown proport patient
clinic benefit two year approxim doubl next best
treatment notabl american societi blood marrow transplant
asbmt endors transplant standard care system sclerosi june
base data random control trial demonstr improv overal
surviv lower rate diseas progress howev elig
patient multipl sclerosi scleroderma europ receiv
transplant risk associ procedur magenta hope
multifacet effort improv morbidity/mort associ transplant
streamlin clinic workflow associ administr enabl
small studi translat meaning chang standard care
magenta develop pipelin small molecul biolog cell therapi aim
improv expand bone marrow transplant option patient
autoimmun diseas blood cancer genet diseas medicin aim
address challeng stem cell sourc engraft stem cell
mobil condit toxic gvhd compani aim three
clinic program multipl indic product develop
use independ combin product magenta believ
significantli alter risk benefit stem cell transplant allow util
wider rang patient debilit diseas
pre-transpl condit tradit perform total bodi irradi
chemotherapi caus damag numer bystand cell bone marrow
stroma lung reproduct organ etc perform vital function kill
tumor cell recipi nativ immun system magenta believ target
antibody-drug conjug approach allow focus effect
kill target cell therebi increas efficaci also reduc toxic
transplant process magenta pipelin contain three program
util antibodi specif differ cell surfac marker
undisclos hematopoietic/immun cell magenta believ differ
express pattern surfac marker may allow optim
differ transplant indic
antibodi adc previous optim compani seattl
genet peaker direct tumor kill limit destruct healthi
tissu order best accomplish task antibodi gener design
long half-liv adc util toxin preferenti kill rapidli
divid cell magenta believ use condit must somewhat
differ properti specif must rel short half-lif
enabl donor stem cell infus engraft prior patient succumb
induc bone marrow failur condit regimen toxin must
capabl kill hematopoiet stem cell may rapidli divid magenta
optim program characterist plan
begin nomin clinic candid around clinic develop begin
magenta advanc condit program target also known
c-kit highli express hsc leukemia aml gener
found surfac differenti immun cell cell cell macrophag
etc endotheli cell therefor magenta believ good condit
target use transplant associ aml genet condit beta-
thalassemia sickl cell diseas possibl combin stem cell direct
preclin data program present studi
magenta show singl dose capabl deplet human
hsc use nsg mous model importantli neither isotyp control
nake antibodi capabl deplet hsc model magenta also
demonstr express aml cell line also enabl
nake antibodi elimin aml cell mous xenogradt model
import standard care treatment aml md
chemotherapi induc remiss follow allogen bone marrow transplant
patient dont achiev complet respons cr inelig transplant
transplant aliv five year follow magenta
hope abil directli kill aml cell could increas number patient
reach cr therebi success abl move transplant
addit complet kill aml cell may allow patient achiev mrd- cr
believ predict superior relaps free surviv follow transplant
addit mous data present bmt tandem present
magenta demonstr adc abil kill human hsc dose
depend could effect mediat short half-lif spare
cell express t-cell b-cell
final magenta demonstr singl infus amanitin
base toxin licens heidelberg pharma could deplet hsc clear
time success transplant occur day
magenta test non-human primat nhp
magenta releas data initi single-dos escal studi wild-typ
non-human primat aim assess adc abil deplet
hsc within unmanipul anim model conserv non-human
primat human data demonstr signific dose-depend
deplet bone marrow six day treatment dose mg/kg
human mice nake antibodi control signific
impact hsc bone marrow preliminari safeti data show transient dose-
depend elev liver enzym group treat non-target
highest dose one non-human primat treat highest dose
level euthan plan bone marrow aspir two addit
primat two highest dose group show sign bone marrow failur
euthan end trial elimin host hsc would expect
result bone marrow failur therefor consid observ bone marrow
failur on-target sign efficaci rather true safeti signal
second dose-escal studi non-human primat perform
engin shorter half-lif lower number drug molecul
per antibodi two vs four prior compound on-going studi aim
achiev deplet shorter half-lif antibodi reduc off-target liver
toxic excess payload identifi maximum toler dose trial
consist two phase part singl ascend dose
administ one three dose level part magenta plan explor multi-
initi pk data part experi present bmt tandem
data demonstr magenta antibodi modif aim reduc half-lif
success gener antibodi hour half-lif increas
clearanc rate rel wild-typ antibodi magenta subsequ disclos
addit inform regard part indic substanti deplet
observ short half-lif antibodi well toler two lower
dose highest dose one nhp experienc elev liver enzym decreas
bodi temperatur subsequ euthan two nhp dose
remain studi magenta goal studi identifi well toler regimen
result clearanc hsc short half-lif consult agre
target profil report clearanc requir current
condit regimen rare achiev full kill instead reli upon graft
elimin remain host hsc complet chimer achiev consult also
note data bluebird bio shibutani autolog gene therapi program
indic littl engraft use applic
physician feel set may particularli attract develop
entir antibodi base condit regimen full data nhp studi
expect present
base upon emerg non-human primat data magenta plan nomin
offici clinic candid program around would allow ind-
enabl studi occur clinic develop begin
potenti direct activ aml/md unmet need within
indic larg magenta plan begin clinic develop transplant elig
aml/md patient possibl endpoint includ safeti toler measur
deplet engraft final relaps free surviv safeti establish
magenta plan expand program aml/md patient frail
pursu transplant current regimen well non-malign diseas
kill lymphocyt patient cell could mediat reject
graft therefor magenta plan supplement kill fludarabin and/or
atg kill cell prevent graft failur consult report busulfan
radiat toxic portion current condit regimen therefor
believ regimen fludarabin like superior safeti profil
magenta estim approxim patient europ
diagnos aml everi year abl achiev remiss
chemotherapi make elig transplant actual
receiv transplant consult report larg driven analysi
remain patient frail toler transplant process despit know
patient like relaps die aml without transplant fact calgb
analysi publish juli indic among treatment nave aml patient
achiev cr dont receiv transplant diseas free surviv rate
among patient age less respect
incid md lower diagnos annual europ
smaller percentag achiev diseas control suffici contempl
transplant elig actual receiv transplant
magenta believ improv outcom patient would otherwis
receiv transplant use standard condit agent expand number
aml md patient achiev remiss and/or deem fit enough pursu
magenta second condit program target antigen
present hematopoiet cell except erythrocyt plasma cell
express somewhat broader therefor could reduc need
fludarabine/atg rel addit direct b- t-cell kill could make
better suit use auto-immun indic ms scleroderma etc
immun cell compart must reset express
broader also variabl within cell type malign therefor magenta
consult believ target cell kill may less complet
magenta report month behind preclin develop
preclin data laboratori david scadden magenta co-found use
publish natur data indic
within mous model abl deplet hsc dose depend
manner significantli nake antibodi unabl mediat cell kill
research went demonstr mice treat antibodi
could success transplant achiev chimer month
furthermor post-transpl cell count recoveri faster mice
condit compar mice condit irradi
author believ differenti reconstitut speed may driven radiat
induc damag bone marrow architectur
magenta plan announc develop candid program
enabl ind file first studi patient
lymphoma leukemia follow autoimmun diseas ms
scleroderma endpoint may includ safeti toler deplet immun cell
deplet relaps prevent mani multipl sclerosi patient could
benefit autolog transplant less patient receiv
transplant consult report larg due morbid mortal
associ receiv transplant magenta believ program could
significantli reduc morbid transplant enabl signific expans
transplant autoimmun
magenta third condit program target undisclos cell surfac marker
specif cell magenta develop goal optim cell
deplet therapi blood cancer prevent stem cell reject prior
allogen bone marrow transplant immun system reset autolog
bone marrow transplant autoimmun diseas patient result could
develop independ exist condit regimen part novel
combin either
magenta plan initi studi chemotherapi spare condit regimen
aml/md patient manag report market research indic
 aml md patient abl achiev diseas control suffici support
transplant unfortun cibmtr data indic
patient actual receiv transplant consult report discrep
larg driven often elderly/frail popul unabl toler
associ transplant
magenta hope use condit agent dramat shift
risk benefit analysi expand use transplant aml/md ultim mani
indic transplant shown confer benefit
consult agre goal anticip magenta success
reduc ae profil transplant howev improv condit alon
expect significantli impact incidence/sever gvhd also
signific factor risk benefit analysi transplant therefor consult
split regard abil and/or dramat chang
frequenc transplant result model conserv
assumpt magenta regimen improv warrant broad use within
current aml/md transplant popul drastic reevalu
receiv transplant
biolog price peak penetr aml/md transplant
market would support global sale within myeloid
malign think even limit success indic would bode well
similar level success nhl transplant multipl myeloma
transplant ultim support sale less patient
indic deem fit transplant therefor bullish view
magenta regimen shift signific number liquid tumor patient fit
transplant categori could provid upsid estim addit sourc
upsid would similar shift fit transplant popul within non-
oncolog indic multipl sclerosi patient scleroderma
cowen compani
due morbid associ bone marrow aspir peripher blood base
donat gener prefer non-cord blood base donat howev
requir hsc mobil bone marrow peripher blood
achiev daili inject g-csf and/or plerixafor two main
limit current approach inconsist time mobil
suffici number cell lack efficaci patient granulocyt colony-
stimul factor g-csf take week inject patient never
gener enough product consult report lack predict
line g-csf line g-csf plerixafor mobil requir reserv
apheresi chair sever consecut day hope donor
achiev suffici mobil use peripher blood one
appoint consult note creat tremend ineffici
donat system cost transplant center time money consult estim
simpli streamlin donat process sever apheresi reserv
one would worth thousand dollar per donor clinic center addit
g-csf contraind certain patient popul sickl cell diseas
known exacerb autoimmun diseas therefor patient undergo auto-
transplant indic gener requir bone marrow aspir recent
bluebird bio report success mobil stem cell sickl cell patient
use gene therapi use plerixafor monotherapi plerixafor approv use
combin g-csf second line mobil hsc gener
annual sale sanofi sale forc
agonist protein prompt neutrophil releas proteas
lead releas hsc blood mechan requir use
g-csf thought complementari plerixafor base multipl anim
model ind-en studi combin plerixafor underway ind
expect goal develop singl day mobil
 year aml/md patient transplant receiv transplant penetr magenta condit transplant util magenta condit magenta condit regimen condit regimen revenu growth y/i aml/md patient transplant receiv transplant penetr magenta condit transplant util magenta condit magenta condit regimen condit regimen revenu condit regimen revenu growth y/i cowen
variou mechan place retain hsc bone marrow
chemokin receptor surfac neutrophil activ prevent
neutrophil releas plerixafor antagon receptor allow neutrophil exit
bone marrow anoth chemokin receptor surfac neutrophil
bound prompt neutrophil excret proteas promot releas
bone marrow togeth plerixafor inhibitor gro
bind believ caus rapid releas hsc bone marrow
peripher blood expect enter clinic develop
goal enabl mobil donat occur singl day
decemb research magenta scientif collabor
publish cell hsc first mobil plerixafor
transplant mous model combin result mobil stem
cell within minut addit result harvest led transplant faster
engraft higher level donor cell rel cell mobil
g-csf
magenta next conduct mobil experi non-human primat data
experi present indic
plerixafor gener significantli cell mobil
plerixafor monotherapi within four hour administr magenta conduct
nhp studi confirm plerixafor mobil hsc engraft least
well hsc obtain standard procedur data expect present
magenta report formal pre-ind studi underway compani plan
file ind clinic develop plerixafor
expect begin healthi volunt transit patient multipl
myeloma non-hodgkin lymphoma attempt undergo autolog
transplant like fail g-csf base mobil success magenta plan
expand program also includ patient g-csf
contraind autoimmun sickl cell
anticip follow ind magenta rapidli gener
proof-of-concept data demonstr mobil stem cell human
cell easili detect blood expect mobil within hour mgta-
administr believ enabl magenta quickli initi
registr trial magenta intend posit plerixafor first line
stem cell mobil agent elimin need use g-csf reduc use
plerixafor greatli streamlin workflow apheresi center provid
conveni donor unclear label support line use obtain
simpl measur stem cell blood magenta
demonstr compar clinic outcom patient transplant tradit
mobil vs mobil stem cell conserv assum later
model launch magenta estim mobil ultim requir
plerixafor plerixafor sold wac label use day
mobil therefor plerixafor mobil gener direct cost
plerixafor mobil also associ sever unus reserv
fail first line g-csf mobil plerixafor mobil consult
estim lost revenu unus reserv sever thousand dollar
consequ think magenta recogn price least per
mobil even front line set cibmtr report
transplant year magenta believ util peripher
donat therefor estim address market mobil
 peak market penetr similar calcul eu
model peak ww sale upsid estim could also provid
conveni caus peripher donat take market share bone
cowen compani
stem cell util peripher peripher stem cell penetr stem cell donat util revenu growth y/i stem cell util peripher peripher stem cell penetr stem cell donat util revenu growth y/i ww revenu growth y/i cowen
umbil cord blood altern sourc stem cell patient
well-match donor decreas risk gvhd associ cord blood
match requir howev cord blood unit use meet
minimum cell dose base recipi bodi weight though
cord blood unit avail world-wide dose requir mean less
suitabl use bone marrow/peripher donat ethnic impact
likelihood find match cord blood adult caucasian patient
chanc adult patient african descent chanc
studi show combin two umbil cord product doubl cord transplant
produc suffici number stem cell transplant follow infus
cord transient chimer graft typic evolv
domin one graft around day patient receiv doubl cord
transplant similar neutrophil recoveri time singl cord transplant
equival total cell dose higher rate grade ii iv acut gvhd delay
magenta advanc candid allogen stem cell therapi
consist singl cord blood unit expos vitro aryl
hydrocarbon receptor ahr antagonist trigger stem cell expans mainten
undifferenti state increas stem cell dose obtain
singl cord magenta believ increas likelihood find highli
match cord gener faster engraft decreas rate gvhd
potenti improv overal surviv ahr antagonist use
licens novarti april
magenta/novarti conduct phase i/ii trial total patient
receiv cord blood transplant enrol patient suitabl cord identifi
cord blood bank frozen cord ship magenta manufactur facil
thaw cultur week undergo releas
test expand cord ship clinic site magenta ship
expand cord fresh sampl data trial publish cell press
present
baselin cord treat averag cell count
expos two week content
cord increas cell magenta believ level expans suffici
allow store cord use adult transplant compar
current would result caucasian patient adult patient
african descent abl obtain suitabl cord public bank
phase portion trial patient adult pediatr given
myeloabl precondit follow doubl cord transplant contain one
unmanipul cord one expand cord patient
achiev engraft median time neutrophil engraft day
compar favor graft failur median day neutrophil
engraft histor control use condit protocol
allow protocol amend enabl singl cord transplant use
expand cell anoth patient enrol portion trial
patient achiev engraft median time neutrophil recoveri
day patient enrol receiv singl cord
engraft median time neutrophil recoveri day compar
favor histor control failur day neutrophil recoveri
non-myeloabl cord blood transplant magenta report safeti overal
surviv small single-cord trial gener consist singl cord
base upon data magenta initi phase ii trial patient
inherit metabol diseas decemb single-arm trial enrol
patient primarili hurler diseas receiv treat cord blood stem cell
myeloabl condit primari endpoint trial rate
neutrophil engraft day initi data trial expect present
late data encourag manag hope move pivot
develop use transplant endpoint neutrophil platelet
recoveri well hospit time similar investigator-initi trial blood
cancer expect begin magenta also plan initi phase ii trial
sickl cell diseas earli
gener approach also potenti util ex vivo expans gene-
modifi hsc regardless sourc right use set
previous outlicens novarti intellia result magenta plan
develop novel small molecul ahr antagonist use set order
gain access gene therapy/edit platform lentivir deliveri
magenta aim develop collabor dedic gene
fda grant orphan drug design transplant gener
without specifi indic transplant use result
hope may receiv broad label rather conduct
dedic diseas specif registr trial regardless think widespread adopt
ultim requir least case seri mani indic like
particularli true within indic transplant benefici rare
data cibmtr indic allogen stem cell transplant
 year number grow rate per year addit
cibmtr report transplant util cord blood-deriv stem
cell consult report declin cord blood cell
use primarili driven increas adopt haploident transplant
prefer haploident larg part due rapid engraft
clinic data indic expand cell also capabl rapid
engraft therefor model declin cord blood share stabil
introduct expand product engraft time variabl cord cord
correl dose contain within cord therefor cord
highest dose baselin may requir expans gener
optim engraft consequ model assum cord blood
transplant benefit peak penetr would lead
transplant year manag plan price mgta-
expand cell line cell therapi howev yet unclear
treat facil magenta respons procur cord blood start
materi model cost clinic cell inclus
procur cord lead peak net revenu
magenta anticip gain approv composit
matter gener method use patent expir magenta
also own patent famili cover use inherit metabol disord
expir magenta also expect fda consid expand cell
refer product therefor think present extra level complex
develop biosimilar
use similar calcul european market transplant somewhat
common estim world-wide revenu
upsid estim could also achiev clinic profil found
superior haploident transplant and/or enabl widespread use
transplant autoimmun indic effect rare util
cowen compani
sever addit compani includ gamida cell nohla therapeut
excellthera also develop expand cord blood product product rang
develop stage phase gamida cell phase excellthera
summar program potenti advantag time
market manufactur timelin etc also without disadvantag baselin
cell dose requir transient engraft etc therefor believ
combin baselin cell dose flexibl manufactur timelin durabl immun
reconstitut could best class
gamida cell develop nicotinamid cord blood stem cell expans agent
result expand cell brand nicord nicord process begin split
cord fraction fraction cryopreserv
later use fraction cultur day nicotinamid
day cultur expand fraction combin fraction
administ transplant patient therefor nicord may increas
allogen stem cell cord blood cord blood benefit ahr base expans elig cord blood penetr cord blood transplant util treat treat cord untreat cord per treat cord cost clinic cord acquisit revenu growth y/i allogen stem cell cord blood cord blood benefit ahr base expans elig cord blood penetr cord blood transplant util treat treat cord untreat cord per treat cord cost clinic cord acquisit revenu growth y/i ww revenu growth y/i cowen
administ cell dose decreas time engraft expand
portion cord avail transplant
phase ii data singl cord nicord transplant present
trial patient enrol receiv nicord graft treatment failur
report occur due fals posit gram stain nicord
product cancel inadequ dose cell within
fraction expand median among treat patient
achiev neutrophil engraft median time engraft day
novemb gamida cell initi random phase trial nicord vs
unmanipul cord blood transplant patient hematolog malign
primari endpoint trial time neutrophil engraft clinicaltri gov
report data trial expect late consult encourag
gamida phase ii data believ trial like posit howev
note gamida manufactur protocol take week vs week
magenta gamida protocol requir patient obtain cord alreadi
possess stem cell dose adequ transplant therefor believ
magenta approach superior
nohla develop notch ligand use ex vivo expans
cord blood stem cell nohla report result fold stem cell
expans expand stem cell refer data phase trial
patient receiv doubl cord transplant unmanipul cord
publish natur medicin report includ data patient
indic neutrophil engraft achiev patient achiev
median day cell deriv expand cord common
initi period follow-up long term evid expand graft found
patient one patient ultim lost evid expand graft
year second patient cell deriv
expand cord day cell expand graft result nohla
develop rapidli engraft product bridg patient
engraft second cord
data patient singl arm phase ii trial present eha
present compar experi patient concurr treat
random control cohort patient receiv standard cord blood
neutrophil engraft median time engraft day vs
day control cohort direct improv rate grade acut
diseas free surviv vs overal surviv vs also
report base upon data ema grant prime design june
nohla complet enrol random phase ii trial cord blood
transplant /- patient hematolog malign primari
endpoint trial time neutrophil engraft clinicaltri gov indic
data expect
excellthera develop pyrimidoindol deriv use expand
cord blood stem cell day manufactur process expand cell
result expand cell product term two phase i/ii trial
investig sponsor phase i/ii trial hematolog malign design
enrol patient suitabl cord identifi use standard criteria
cells/kg patient enrol three cohort progress
lower limit cell addit expand
cord two addit cord cells/kg requir avail one
use main doubl cord procedur second use emerg back-up
cord primari endpoint trial safeti secondari measur transplant
success includ hematopoiet recoveri june excellthera report
final patient treat protocol preliminari data indic
approach safe feasibl
second phase i/ii trial began march expect enrol multipl
myeloma patient receiv nonmyeloabl condit follow transplant
consult intrigu seven day product process
unsur expand stem cell result long term immun system
equival standard transplant
magenta also on-going preclin research program prevent gvhd
exist acut gvhd prevent treatment includ prophylact use non-specif
immun suppress agent increas risk infect addit
treatment limit efficaci allogen transplant patient still
experienc acut gvhd magenta develop select elimin
alloreact cell compon donor graft caus acut gvhd
therapi meant vivo dose time transplant prevent onset
gvhd antigen target disclos magenta anticip start
ind enabl studi
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
magenta unprofit approv product like need rais
addit capit public market prior turn profit much magenta
pipelin yet enter clinic test therefor compani face number
clinic regulatori commerci hurdl prior becom success make
invest recommend earli stage pre-commerci biotechnolog compani
base upon assess technolog probabl pipelin success
potenti market opportun event success howev compani
lack tradit financi metric believ good methodolog
assign specif target price stock
